Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2833–2856 of 10,535 matching trials from the live ClinicalTrials.gov search.
Filters: Active, not recruiting Clear all
Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

NCT04234568
View directory record Official record
Conditions
Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor
Interventions
Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Triapine
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Phase 3 Interventional

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

NCT04833140
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Estradiol patch, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Not applicable Interventional

Telehealth Stepped Exercise Program for Rural Veterans With Knee Osteoarthritis

NCT04775589
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Stepped Exercise for Knee Osteoarthritis
Behavioral
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Not applicable Interventional

Brain Boosters 2 in Persons at Risk for Alzheimer's Disease: a Digital Application Supported Intervention

NCT05027789
View directory record Official record
Conditions
Memory Disorders, Cognitive Impairment
Interventions
Self-Guided, Structured Group
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
65 Years to 90 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Phase 2 Interventional

Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04754191
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Enfortumab vedotin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Not applicable Interventional

Testing the Engaged Approach to Lung Cancer Screening

NCT06327074
View directory record Official record
Conditions
Lung Cancer
Interventions
Engaged Approach to Lung Cancer Screening
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer

NCT03400215
View directory record Official record
Conditions
Breast Cancer
Interventions
Diagnostic Breast Cancer Scan, Research Scan for Gradient-echo Spectroscopic Imaging (GSI)
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
25 Years to 99 Years · Female only
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

NCT05627635
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8
Interventions
Balstilimab, Bevacizumab, Biospecimen Collection, Botensilimab, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, X-Ray Imaging
Biological · Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Not applicable Interventional

Integrated Actionable Aging Assessment for Cancer Patients Pilot

NCT05871008
View directory record Official record
Conditions
Breast Cancer, Hodgkin Lymphoma, Kidney Cancer, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia, Prostate Cancer, Bladder Cancer
Interventions
Assessment tool IA3-CP with SDoH, Assessment tool IA3-CP without SDoH
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
65 Years to 111 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Phase 1 Interventional

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

NCT04526691
View directory record Official record
Conditions
Advanced or Metastatic NSCLC
Interventions
Datopotamab deruxtecan, KEYTRUDA®, Carboplatin, Cisplatin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Treatment for Speech and Language in Primary Progressive Aphasia

NCT04881617
View directory record Official record
Conditions
Primary Progressive Aphasia, Semantic Dementia, Semantic Memory Disorder, Logopenic Progressive Aphasia, Nonfluent Aphasia, Progressive, Aphasia, Aphasia, Progressive
Interventions
Lexical Retrieval Training (LRT), Video-Implemented Script Training for Aphasia (VISTA)
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
2
States / cities
San Francisco, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Phase 2 Interventional

Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

NCT05466890
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative, Ulcerative Colitis Flare
Interventions
PL8177 Placebo, PL8177
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Tucson, Arizona • Lancaster, California • Tarzana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Phase 1 Interventional

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

NCT05378425
View directory record Official record
Conditions
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
Interventions
NTX-1088, Pembrolizumab
Drug
Lead sponsor
Nectin Therapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Duarte, California • New Orleans, Louisiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Not applicable Interventional

Memory Retrieval and Encoding Investigated by Neural Stimulation

NCT04286776
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Direct electrical stimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Phase 2 Interventional

Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

NCT05723055
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Axatilimab, Nivolumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Detroit, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Phase 2 Interventional

CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

NCT04322955
View directory record Official record
Conditions
Kidney Cancer, Renal Cell Carcinoma
Interventions
Cabozantinib, Nivolumab, Cytoreductive nephrectomy
Drug · Procedure
Lead sponsor
Mark Stein
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
4
States / cities
New Brunswick, New Jersey • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

NCT03197506
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions
External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy, Temozolomide, Therapeutic Conventional Surgery
Radiation · Other · Biological + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
3
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Phase 2Phase 3 Interventional

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
19
States / cities
La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Phase 1 Interventional

VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

NCT03769155
View directory record Official record
Conditions
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Interventions
Ipilimumab, Nivolumab, VX15/2503, Surgery
Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

CharacterIzation of Adult Onset Autoimmune Diabetes

NCT03971955
View directory record Official record
Conditions
Diabetes
Interventions
Mixed Meal Test, Dual Energy X-Ray Absorptiometry (DEXA), Adipose Tissue Biopsy
Other · Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Phase 2Phase 3 Interventional

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

NCT06506955
View directory record Official record
Conditions
Advanced/Metastatic Cancer
Interventions
futibatinib, futibatinib, fulvestrant
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Not applicable Interventional

Digital Otoscopy Versus Standard Otoscopy on the Diagnosis and Treatment of Otitis Media in Young Children

NCT07328555
View directory record Official record
Conditions
Otitis Media, Antimicrobial Stewardship
Interventions
Device: Digital Otoscope
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Wellesley, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Phase 2 Interventional

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

NCT02750358
View directory record Official record
Conditions
Breast Cancer, Early Stage, Triple Negative Breast Cancer
Interventions
Enzalutamide, assessment
Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
12
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 15, 2026, 5:13 AM EST
Active, not recruiting Not applicable Interventional

US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

NCT05232838
View directory record Official record
Conditions
Hydrocephalus, Normal Pressure, Hydrocephalus
Interventions
eShunt Implant
Device
Lead sponsor
CereVasc Inc
Industry
Eligibility
65 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
New Haven, Connecticut • Jacksonville, Florida • Kansas City, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Nov 15, 2026, 5:13 AM EST